1[1]Grossman JD，Bishop A.Deficient cellular cyclic AMP may cause both cardiac and skeletal muscle dysfunction in heart failure.J Card Fail,1996,2(4 Suppl)∶S105-111.
2[2]Gao M,Ping P.Increased expression of adenylycyclase type Ⅵ proportionely cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA,1998,95(3)∶1038-1043.
3[3]Money-Kyrle AR,Davies CH,Ranu HK,et al.The role of cAMP in the frequency-dependent changes in contraction of guinea-pig cardiomyocytes.Cardiovasc Res,1998,37(2)∶532-540.
4[4]Schmidt U,Hajjar RJ,Kim CS,Lebeche D.Human heart failure: cAMP stimulation of Ca2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol,1999,277(2pt2)∶H474-480.
5[5]Kirchhefer U,Schmitz W,Scholz H,et al.Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human.Cardiovasc Res,1999,42(1)∶254-261.
6[6]Mulieri LA,Leavitt BJ,Wright RK.Role of cAMP in modulation kinetics and the fouce-frequency relation in mitral regurgitation heart failure.Basic Res Cardiol,1997,92∶95-103.
7[7]Nakanishi M,Yokota Y,Fukuzaki H.Cardiovascular effects of dibutyryl cyclic AMP in patients with congestive heart failure-comparison with dobutamine and captopril.Jpn Circ J,1988,52(6)∶503-510.
8[8]Hoshino Y.Cute effects of dibutyryl cyclic AMP on renal circulation in congestive heart failure.Jpn Heart J,1988,29(6)∶711-719.
